Totally agree with your sentiments Intowin.
Prima's projected revenue statements are based on 10% of the current ovarian cancer market. In reality, if (when) pivotal phase 3 trials are successful, this will be a very conservative projection in the early years.
There is plenty of room for'competitors',who in all likely hood will not be competitors at all due to the many and various mutations of cancer, which one drug/therapy could never possibly treat.
Totally agree with your sentiments Intowin.Prima's projected...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
39.5¢ |
Change
-0.005(1.25%) |
Mkt cap ! $562.6M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.5¢ | 39.5¢ | $754.0K | 1.894M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 40712 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 2454 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2024 (20 minute delay) ? |
| IMM (ASX) Chart |